{"id":"chop-combined-with-cmab304","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Cardiotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CHOP is a standard combination chemotherapy regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) that kills rapidly dividing cancer cells. CMAB304 is a monoclonal antibody that likely enhances anti-tumor immunity or blocks a specific tumor-associated target. The combination aims to improve efficacy over chemotherapy alone by leveraging both cytotoxic and immunological mechanisms.","oneSentence":"CHOP chemotherapy combined with CMAB304 (a monoclonal antibody) targets cancer cells through cytotoxic chemotherapy while enhancing immune response through antibody-mediated mechanisms.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:05:48.090Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Lymphoma or hematologic malignancy (specific indication not publicly confirmed)"}]},"trialDetails":[{"nctId":"NCT01459887","phase":"PHASE3","title":"Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Shanghai CP Guojian Pharmaceutical Co., Ltd.","startDate":"2006-09","conditions":"Diffuse Large B Cell Lymphoma","enrollment":278}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["cyclophosphamide, doxorubicin, vincristine, prednisone"],"phase":"phase_3","status":"active","brandName":"CHOP combined with CMAB304","genericName":"CHOP combined with CMAB304","companyName":"Shanghai CP Guojian Pharmaceutical Co., Ltd.","companyId":"shanghai-cp-guojian-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CHOP chemotherapy combined with CMAB304 (a monoclonal antibody) targets cancer cells through cytotoxic chemotherapy while enhancing immune response through antibody-mediated mechanisms. Used for Lymphoma or hematologic malignancy (specific indication not publicly confirmed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}